# A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

> **NCT07260500** · PHASE2 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Short Stature Children Born Small for Gestational Age (SGA)

## Interventions

- **DRUG:** PEG-rhGH Injection
- **DRUG:** hGH Injection

## Key facts

- **NCT ID:** NCT07260500
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2026-12-23
- **Final completion:** 2027-04-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260500, "A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07260500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*